Brad S. Kahl

Aug 6, 2024 | nature.com | Ting Liu |Michael He |Maja Ludvigsen |Maher Gandhi |Christian Steidl |Jan Delabie | +2 more

AbstractFollicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-treatment tumor tissue samples. Our analysis revealed the existence of five subtypes with unique genetic profiles that correlated with clinicopathological characteristics.

Jul 8, 2024 | cancernetwork.com | Brad S. Kahl |Tycel J. Phillips

2 Commerce Drive Cranbury, NJ 08512

Jun 27, 2024 | cancernetwork.com | Brad S. Kahl |Tycel J. Phillips

June 27, 2024By The panelists evaluate the preliminary efficacy findings from the ECHO trial and address how the COVID-19 pandemic influenced overall survival outcomes in the study. What are your initial impressions of the efficacy data from ECHO? How did COVID impact OS for this trial data? Do you have clinical experience with BTKi’s in the frontline setting? If so, please share your experience. Related Content Related Content

Oct 5, 2023 | onclive.com | Brad S. Kahl

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses ongoing and planned investigations within the landscape of mantle cell lymphoma (MCL). The MCL treatment landscape is currently undergoing significant changes, Kahl says, citing the 2022 publication of data from the phase 3 SHINE trial (NCT01776840), which was performed in older patients with MCL.

Sep 8, 2023 | onclive.com | Brad S. Kahl

Brad S. Kahl, MD, a professor in the Department of Medicine, Oncology Division, at Washington University School of Medicine in St. Louis, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma (MCL). The covalent BTK inhibitors zanubrutinib (Brukinsa) and acalabrutinib (Calquence) are currently approved by the FDA for the treatment of patients with MCL who have received at least 1 prior line of therapy.